Companies › AgonOx
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DP CD8 TIL Autologous CD8+ tumor infiltrating lymphocytes enriched for CD39+CD103+ cells, expanded ex | – | Phase 1 | HNSCC | Dec 2026 |
| DP CD8 TIL KD Interleukin-2 receptor agonist | IL2RA, IL2RG, IL2RB | Phase 1 | HNSCC | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05902520 | DP CD8 TIL | Phase 1 | HNSCC | Oncology | Dec 2026 |
| NCT05902520 | DP CD8 TIL KD | Phase 1 | HNSCC | Oncology | Dec 2026 |
CellTrans Sanofi ImmunityBio Nektar Therapeutics Regeneron Pharmaceuticals Mural Oncology PolTREG GI Innovation Synthekine
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.